Eiger BioPharmaceuticals, Inc.
http://www.eigerbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eiger BioPharmaceuticals, Inc.
All Over For Acorda After A Torrid Few Years
The embattled US biotech has gone into Chapter 11 and linked up with 'stalking horse' bidder Merz which has offered $185m to get hold of Ampyra for multiple sclerosis and Parkinson’s therapy Inbrija.
Eiger To Close After GLP-1 Antagonist Gambit Fails
The company had pivoted towards a drug with the opposite mechanism to Novo Nordisk’s Wegovy, but ran out of time and money.
Breakdowns In The Breakthrough Lane: When Recipients Of FDA Expedited Designation Fall Short
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
Finance Watch: FibroGen, Amarin And Others Downsize To Survive
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Celladon Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice